Amneal appoints new chief scientific officer

Press enter to search
Close search
Open Menu

Amneal appoints new chief scientific officer

By Sandra Levy - 04/11/2019
Amneal is welcoming a new chief scientific officer. Pradeep Bhadauria has been named chief scientific officer, succeeding Shankar Hariharan, who is leaving Amneal on May 24.

“Pradeep brings significant R&D expertise to Amneal, including more than 20 years leading the development capabilities for several leading generic and specialty pharmaceutical companies. Throughout his career, his leadership has resulted in the development and filing of more than 200 products, including numerous first-to-file and first-to-market opportunities,” the company said.

“We are excited to have Pradeep join our leadership team at this important moment for Amneal," Amneal president and CEO Rob Stewart said. “His deep R&D expertise across nearly all dosage forms and demonstrated strength in developing complex generics and other difficult-to-formulate products will be a strong asset to our company as we continue to diversify our pipeline and portfolio.”

“I would like to thank Shankar for his exceptional contributions during the last nine years with Amneal,” added Stewart. “His leadership and vision have helped deliver the company to the strong position it stands in today, with robust capability and one of the industry’s largest pipelines. Thanks to his efforts, we are well positioned to continue evolving Amneal to support further pipeline and portfolio growth.”

“I am thrilled to be joining Amneal at this exciting time for the company,” Bhadauria said. “I look forward to working closely with Amneal’s excellent scientific affairs team to help advance and expand the company’s compelling pipeline and continue bringing important treatment options to patients.”

Bhadauria joins Amneal from Apotex, where he most recently served as executive vice president, global R&D, responsible for leading the company’s entire global R&D activities. He also managed a large generic R&D portfolio across many dosage forms for various global markets. Prior to joining Apotex, he served as vice president - generic R&D for Allergan/Actavis.

Bhadauria holds a Master of Pharmacy from the Birla Institute of Technology in India and a Bachelor of Pharmacy from SGSITS, Devi Ahilya University in India . He also holds several patents and has published research in various publications.

Related Topics